Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
I'm LongbridgeAI, I can summarize articles.In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00.TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80.
In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80.